• FirefoxUpgrade to the new Firefox »
  •  Dow Up1.31% Nasdaq Up0.98%

    Trinity Biotech plc (TRIB)

    18.79 0.18(0.95%) Jan 29, 4:00PM EST
    Add to Portfolio
    ProfileGet Profile for:
    Trinity Biotech plc
    IDA Business Park
    Ireland - Map
    Phone: 353 1 276 9800
    Fax: 353 1 276 9888
    Website: http://www.trinitybiotech.com

    Index Membership:N/A
    Industry:Diagnostic Substances
    Full Time Employees:571

    Business Summary 

    Trinity Biotech plc acquires, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market. It offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as bacterial, fungal, parasitic, and viral diseases; autoimmune disorders; products for the in-vitro diagnostic testing for haemoglobin A1c (HbA1c) used in the monitoring and diagnosis of diabetes; Hb variants for the detection of Hemoglobinapothies; and reagent products, such as ACE, bile acids, lactate, oxalate, and glucose-6-phosphate dehydrogenase for detecting liver and kidney diseases, and haemolytic anaemia. The company also provides UniGold HIV, a POC diagnostic test, which is carried out in the presence of the patient to diagnose the presence of HIV antibodies in the patient. In addition, it sells raw materials to the life sciences industry and research institutes. Its customers include hospitals, clinical and reference laboratories, public health facilities, and other outreach facilities. The company sells its products through its direct sales force in the United States; and a network of independent distributors and strategic partners internationally. Trinity Biotech plc was founded in 1992 and is headquartered in Bray, Ireland.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Trinity Biotech plc

    Key Executives 
    Mr. Ronan O , 59
    Co-Founder, Chairman, Chief Exec. Officer and Chairman of Compensation Committee
    Mr. Kevin Tansley , 44
    Chief Financial Officer and Sec.
    Dr. James Walsh Ph.D., 56
    Chief Scientific Officer and Exec. Director
    Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.